Eli Lilly and Company $LLY Shares Sold by TFR Capital LLC.

Key Points

• TFR Capital reduced its Eli Lilly stake by 15.7% in the second quarter, selling 877 shares and retaining 4,709 shares valued at approximately $5.65 million. Institutional investors collectively own 82.53% of LLY.
• Lilly reported strong quarterly results, with EPS of $8.38 versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year. Growth is being driven largely by its obesity-drug portfolio and broader pipeline.
• Analysts remain broadly positive, but valuation and competition are risks. LLY has a “Moderate Buy” consensus rating and a $1,292.18 average price target, while its roughly $1.17 trillion market capitalization and P/E ratio above 41 reflect elevated expectations; insiders also sold shares under pre-arranged trading plans.

TFR Capital LLC. reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,709 shares of the company's stock after selling 877 shares during the quarter. Eli Lilly and Company comprises approximately 1.6% of TFR Capital LLC.'s portfolio, making the stock its 15th biggest holding. TFR Capital LLC.'s holdings in Eli Lilly and Company were worth $5,648,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. One Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 19.6% during the second quarter. One Wealth Advisors LLC now owns 654 shares of the company's stock worth $784,000 after buying an additional 107 shares in the last quarter. Family Legacy Inc. grew its stake in Eli Lilly and Company by 0.7% in the 2nd quarter. Family Legacy Inc. now owns 6,758 shares of the company's stock worth $8,106,000 after acquiring an additional 47 shares during the period. Clearstead Trust LLC raised its holdings in Eli Lilly and Company by 1.0% in the 2nd quarter. Clearstead Trust LLC now owns 6,741 shares of the company's stock valued at $8,085,000 after acquiring an additional 65 shares during the last quarter. Maridea Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 14.7% during the 2nd quarter. Maridea Wealth Management LLC now owns 406 shares of the company's stock worth $487,000 after purchasing an additional 52 shares during the period. Finally, Ridgecrest Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Ridgecrest Wealth Partners LLC now owns 884 shares of the company's stock worth $1,060,000 after purchasing an additional 24 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity portfolio remains the main catalyst. Lilly’s Zepbound sales reportedly increased 46%, while recent coverage indicates its GLP-1 portfolio is outpacing Novo Nordisk’s in the latest quarter. Investors are also watching oral obesity candidates and retatrutide as potential sources of future growth. How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
• Positive Sentiment: Pipeline activity continues across several therapeutic areas. Lilly advanced early-stage studies involving LY4178256, eloralintide, lepodisiran and oral candidate LY4065967, while completing a Phase 3 lebrikizumab trial in atopic dermatitis. These updates do not provide immediate revenue, but they reinforce the company’s longer-term growth prospects. Lilly's Lebrikizumab Trial Completion Signals New Growth Path
• Positive Sentiment: Fundamentals remain strong. Lilly’s latest quarterly earnings and revenue substantially exceeded consensus estimates, with revenue rising 47.7% year over year. Analysts continue to cite GLP-1 momentum and a broad pipeline as reasons for a constructive long-term outlook.
• Neutral Sentiment: Lehigh Valley construction plans emphasize traffic mitigation. Lilly outlined measures intended to reduce disruption from construction, an operational update that may ease local execution concerns but is unlikely to materially affect near-term earnings. Eli Lilly Lehigh Valley Construction Plans
• Negative Sentiment: Valuation and competition are weighing on sentiment. With LLY valued above $1 trillion and trading at a high earnings multiple, investors may be taking profits after its recent rally. Novo Nordisk and potential entrants such as Pfizer are intensifying the race for oral and next-generation obesity treatments, raising future pricing and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LLY shares. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a report on Monday, June 22nd. Finally, Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,292.18.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Down 2.6%

Shares of NYSE:LLY opened at $1,246.89 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 1 year low of $694.23 and a 1 year high of $1,292.65. The stock has a market capitalization of $1.17 trillion, a P/E ratio of 41.84, a PEG ratio of 1.51 and a beta of 0.51. The stock has a 50-day simple moving average of $1,177.74 and a 200-day simple moving average of $1,058.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the firm posted $6.31 earnings per share. Eli Lilly and Company's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source